Edition:
United States

Endo International PLC (ENDP.O)

ENDP.O on Nasdaq

7.88USD
19 Oct 2017
Change (% chg)

$0.23 (+3.01%)
Prev Close
$7.65
Open
$7.59
Day's High
$7.93
Day's Low
$7.50
Volume
6,311,088
Avg. Vol
5,725,661
52-wk High
$21.87
52-wk Low
$7.40

Latest Key Developments (Source: Significant Developments)

Endo International names Paul Campanelli CEO
Friday, 23 Sep 2016 07:00am EDT 

Endo International PLC : Endo names Paul Campanelli president and chief executive officer . Company affirms Q3 and full year 2016 financial guidance . Campanelli succeeds Rajiv De Silva, who has stepped down as president, CEO and a member of board . Q3 earnings per share view $0.82, revenue view $864.5 million -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $4.56, revenue view $3.93 billion -- Thomson Reuters I/B/E/S.  Full Article

Vivus says extends return date of Stendra commercial rights
Monday, 29 Aug 2016 04:30pm EDT 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

Endo International says President and CEO Adopts 10B5-1 trading plan
Thursday, 18 Aug 2016 04:05pm EDT 

Endo International Plc : Says CEP Rajiv De Silva has entered into a rule 10b5-1 stock trading plan in connection with his year-end tax planning . Under terms of de silva's stock plan, third-party broker will sell up to 13,500 endo shares owned by de silva . Endo international says de silva's stock being sold, represents about 4 percent of de silva's total endo stock ownership .Says ceo's stock trading plan will be completed in september 2016.  Full Article

Endo to continue collecting, analyzing data relating to OPANA ER
Friday, 12 Aug 2016 07:00am EDT 

Endo International Plc : Endo announces OPANA ER regulatory update . Plans to continue collecting and analyzing epidemiological data relating to OPANA ER . Financial projections for 2016 did not assume approval of SNDA . Endo announces OPANA ER regulatory update .Says has decided to withdraw its supplemental new drug application (SNDA) relating to specific abuse deterrent labeling for OPANA ER.  Full Article

Endo posts Q2 adj. earnings $0.86/shr from continuing operations
Monday, 8 Aug 2016 04:28pm EDT 

Endo International Plc : Endo reports second quarter 2016 financial results . Q2 adjusted earnings per share $0.86 from continuing operations . Q2 revenue $921 million versus I/B/E/S view $863.9 million . Q2 GAAP earnings per share $1.75 from continuing operations . Q2 earnings per share view $0.74 -- Thomson Reuters I/B/E/S . During Q2 2016, company recorded pre-tax, non-cash impairment charges of $40.0 million .Affirming our full year 2016 revenue and adjusted diluted EPS financial guidance.  Full Article

Endo International to terminate supply agreement
Monday, 18 Jul 2016 06:07pm EDT 

Endo International Plc : Effective date of termination is April 27, 2017- SEC filing . Endo is terminating supply agreement in accordance with terms; termination will not give rise to early termination fees, penalties .Unit provided written notice to Noramco, Inc that Endo was terminating supply agreement, dated as of April 27, 2012.  Full Article

Vivus says to extend return date of Stendra commercial rights
Thursday, 30 Jun 2016 04:15pm EDT 

Vivus Inc : Vivus Inc says to extend return date of Stendra commercial rights .Extension of termination date of license agreement between Auxilium Pharmaceuticals and Vivus for Stendra â U.S. and Canadian commercial rights through August 31.  Full Article

Endo International announces issuance of Vasostrict patent
Tuesday, 28 Jun 2016 12:34pm EDT 

Endo International Plc : Endo announces issuance of Vasostrict® patent . Patent no. 9,375,478 has been submitted to FDA's Approved Drug Products; to have submission date of June 28 .New patent by PTO relating to Vasostrict has an expiration date of January 30 , 2035.  Full Article

Endo says FDA advisory committee for Opana will be convened in fall of 2016
Wednesday, 15 Jun 2016 08:30am EDT 

Endo Pharmaceuticals Inc : Has been notified that an advisory committee of FDA will be convened in fall of 2016 . Advisory committee of FDA will be convened to review company's supplemental new drug application (SNDA) for Opana® ER .Current prescription drug user fee act (PDUFA) date of july 29, 2016 for Opana ER SNDA will not be met.  Full Article

Monosol Rx wins patent infringement suit against Par pharma, Watson pharma
Tuesday, 7 Jun 2016 11:04am EDT 

Monosol Rx : Monosol Rx Wins Patent Infringement Suit Against Par Pharmaceutical And Watson Pharmaceuticals Related To Suboxone Sublingual Film .Ruling Expected To Prevent Generic Buprenorphine, Naloxone Film Products From Entering Market Prior To The Patent’S Expiration In 2024.  Full Article

Photo

U.S. asks drug maker Endo to withdraw opioid amid abuse crisis

WASHINGTON As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc to withdraw from the market its long-lasting opioid painkiller, Opana ER, sending Endo's shares down more than 12 percent.